Finasteride 1mg / 5mg (Propecia & Proscar)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Finasteride 1mg / 5mg (Propecia & Proscar). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
Propecia (Finasteride) — Dosage Strengths & Online Availability
| Dosage Strength | Pack Supply | Dispensary Price | Stock Status | Verified Order |
|---|---|---|---|---|
| Propecia 1mg | Film-Coated Tablets • 30 / 60 Units | $2.38 / unit | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
| Propecia 5mg POPULAR | Film-Coated Tablets • 60 / 90 Units (Most Popular) | $1.27 / unitPOPULAR | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
1. Clinical Dosing & Titration Protocols
Daily / Baseline Regimen
Male Androgenic Alopecia (Hair Loss): 1 mg orally once daily with or without food. Continuous daily use for >=6 months is required to assess regrowth. BPH: 5 mg once daily.
On-Demand / Titration Regimen
Not applicable. Requires steady daily inhibition of 5-AR enzyme.
Strictly contraindicated in pregnant women (Category X; causes genital feminization in male fetuses).
2. Patient Administration & Safe Usage Guidelines
Hair regrowth and shedding cessation typically require 3 to 6 months of daily therapy. Discontinuation leads to gradual reversal of hair gains over 9–12 months.
Verified Telehealth Access Standards for Finasteride 1mg / 5mg (Propecia & Proscar)
Our clinical editorial board audits certified partner telehealth dispensaries to guarantee authentic WHO-GMP manufacturing, analytical batch testing, and physician-supervised asynchronous consultation.
Check Telehealth Protocol & Availability ↗3. Frequently Asked Patient Questions
How does Finasteride stop hair loss?
Finasteride inhibits the 5-alpha reductase enzyme that converts testosterone into dihydrotestosterone (DHT). By reducing scalp and serum DHT by 70%, hair follicles recover from miniaturization and resume thick terminal hair growth.
Does 1mg Finasteride lower total testosterone?
No. By blocking the conversion of testosterone into DHT, free and total serum testosterone levels actually increase slightly (by ~10–15%) within the normal physiological range.
4. Pharmacological Mechanism & Receptor Profile
Competitive inhibitor of Type II 5-alpha reductase that suppresses dihydrotestosterone (DHT) by 70%, stopping follicular miniaturization and reversing male pattern hair loss.
Urology & Men's Health • Finasteride 1mg / 5mg (Propecia & Proscar)
5. Chemical & Human Pharmacokinetic Matrix (Tmax, Half-Life, CYP450)
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | 1.0 to 2.0 hours | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 6.0 hours (prolonged tissue binding in prostate and hair follicles) | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | 9.2 ng/mL (1mg) | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | 65% (unaffected by food) | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 90% | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 76 Liters | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Extensively metabolized by hepatic CYP3A4 | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | 57% feces, 39% urine as metabolites | Renal vs biliary/fecal excretion balance. |
6. Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| No major CYP450 pharmacokinetic contraindications identified. | Safe | Well-tolerated with standard medications. |
7. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Decreased Libido | 1.8% | Transient; resolves with continued therapy or discontinuation. |
| Erectile Dysfunction | 1.3% | Reversible. |
| Decreased Ejaculate Volume | 0.8% | Benign reduction in seminal fluid. |
Peer-Reviewed Scientific Citations & FDA References
- Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.